The goal is to optimize future therapeutic strategies by exploring lifestyle changes, pharmacological agents, surgical approaches, and the gut microbiome in NASH treatment, focusing on insulin sensitizers, thyroid hormone mimetics, antioxidants, and other potential targets, thereby lowering the mortality rates [20]. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.